^
Association details:
| Biomarker: | FGFR3 S249C |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | pazopanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Spectrum of genomic alterations in FGFR 3 : current appraisal of the potential role of FGFR 3 in advanced urothelial carcinoma
Excerpt:
To explain this patient's robust outlier response to pazopanib, we genomically analysed the tumour using targeted mutation profiling (Foundation Medicine, Cambridge, MA, USA), which revealed a sole activating mutation in FGFR3 (S249C). The sole presence of a mechanistically confirmed activating mutation and potent response to pazopanib is consistent with the hypothesis that FGFR3 was a molecular driver in this patient with UC...
DOI:
https://doi.org/10.1111/bju.13552
